NCT03877055View on ClinicalTrials.gov

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
DRUG

Copanlisib

Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.

DRUG

Ibrutinib

Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03877055 - A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter